Fusion Pharmaceuticals (NASDAQ:FUSN) Stock Rating Reaffirmed by TD Cowen

Fusion Pharmaceuticals (NASDAQ:FUSN)‘s stock had its “hold” rating restated by investment analysts at TD Cowen in a research report issued on Tuesday, Benzinga reports.

A number of other equities research analysts have also weighed in on FUSN. Raymond James reaffirmed a “market perform” rating on shares of Fusion Pharmaceuticals in a report on Tuesday, March 19th. Truist Financial reiterated a “hold” rating and set a $21.00 price objective (up from $11.00) on shares of Fusion Pharmaceuticals in a research note on Tuesday, March 19th. Bloom Burton downgraded shares of Fusion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, March 20th. B. Riley downgraded shares of Fusion Pharmaceuticals from a “buy” rating to a “neutral” rating and increased their price objective for the company from $13.00 to $23.00 in a research note on Wednesday, March 20th. Finally, Leerink Partnrs downgraded shares of Fusion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Tuesday, March 19th. Thirteen investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, Fusion Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $20.25.

Fusion Pharmaceuticals Stock Performance

Shares of FUSN stock opened at $21.24 on Tuesday. Fusion Pharmaceuticals has a one year low of $2.31 and a one year high of $21.55. The company has a debt-to-equity ratio of 0.16, a quick ratio of 15.01 and a current ratio of 15.01. The company has a 50 day moving average price of $15.67 and a 200 day moving average price of $9.63. The firm has a market capitalization of $1.80 billion, a price-to-earnings ratio of -14.45 and a beta of -0.72.

Fusion Pharmaceuticals (NASDAQ:FUSN) last released its quarterly earnings data on Wednesday, March 20th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.05). Fusion Pharmaceuticals had a negative return on equity of 46.59% and a negative net margin of 4,136.55%. Sell-side analysts anticipate that Fusion Pharmaceuticals will post -1.46 EPS for the current year.

Hedge Funds Weigh In On Fusion Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP acquired a new position in shares of Fusion Pharmaceuticals in the 4th quarter worth approximately $7,154,000. Goldman Sachs Group Inc. purchased a new stake in shares of Fusion Pharmaceuticals in the 4th quarter valued at approximately $145,000. Chartwell Investment Partners LLC acquired a new position in Fusion Pharmaceuticals in the 4th quarter worth approximately $480,000. Pier Capital LLC acquired a new stake in Fusion Pharmaceuticals during the 4th quarter valued at $2,663,000. Finally, Weiss Multi Strategy Advisers LLC acquired a new stake in Fusion Pharmaceuticals during the 4th quarter valued at $1,656,000. Institutional investors and hedge funds own 72.85% of the company’s stock.

Fusion Pharmaceuticals Company Profile

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor.